News
EARS
--
0.00%
--
Auris Medical shares rise on OligoPhore Lymphoma study results
Auris Medical Holding shares jump ([[EARS]] +8.1%) after the company announced the publication of positive results from an in vivo study demonstrating "significant inhibition of tumor growth" by siRNA knock-down of NF-κB employing
Seekingalpha · 5h ago
Auris Medical Stock Trading Higher After OligoPhore Technology Shows Tumor Inhibition In Animal Studies
Benzinga · 5h ago
Auris Medical Shares Rise 15% on Positive Results for Lymphoma Treatment
marketwatch.com · 6h ago
Auris Medical Announces 'Significant Inhibition Of Tumor Growth 'With OligoPhore siRNA Targeting NF-κB In Murine Model Of Adult T-Cell Leukemia / Lymphoma
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma Treatment with OligoPhoreTM siRNA stops aggressive
Benzinga · 7h ago
Auris Medical Reports Positive Results From In Vivo Study of Potential Lymphoma Treatment
MT Newswires · 8h ago
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2)
Benzinga · 06/03 12:23
BB, WKHS, SNDL and GEO among notable premarket gainers
Jiuzi Holdings (JZXN) +49%.GTT Communications (GTT) +28%.Community Bankers Trust Corporation ESXB +26% on merger agreement with United Bankshares.Tellurian TELL +26% on 10-year LNG sales deal with Vitol.Workhorse Group (WKHS) +16%.Auris Medical Holding (EA...
Seekingalpha · 06/03 12:23
Auris Medical soars 10% on acquisition of Trasir Therapeutics and plans for strategic repositioning
Auris Medical Holding (EARS) jumps 10% premarket after acquiring privately held Trasir Therapeutics, based in Tampa, FL.The purchase price comprises 0.77M common shares of the acquiring Company, the assumption of certain selling
Seekingalpha · 06/03 12:13
Auris Medical Acquires Trasir, Plans Strategic Repositioning
By Michael Dabaie Auris Medical Holding Ltd. said it acquired privately held Trasir Therapeutics Inc. The purchase price comprises 770,000 common shares of...
marketwatch.com · 06/03 12:13
BRIEF-Auris Medical Announces Acquisition Of Rna Therapeutics Company And Plans For Strategic Repositioning
reuters.com · 06/03 11:36
Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning
Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc.Trasir’s innovative peptide-based OligoPhoreTM platform designed to enable extrahepatic delivery of oligonucleotidesTrasir’s founder, Dr. Samuel Wickline, joining leadership...
GlobeNewswire · 06/03 11:30
BRIEF-Auris Medical Starts Preparations For Covid-19 Trial With Bentrio In India
reuters.com · 06/01 12:57
Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Auris Medical Holding (EARS) announces that its affiliate Altamira Medica has started preparations to conduct a study with its Bentrio nasal spray for protection against airborne viruses and allergens in India.The study will seek
Seekingalpha · 06/01 12:51
Auris Medical Says Starting Preparations For COVID-19 Trial With Bentrio in India
Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its
Benzinga · 06/01 12:38
Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India
Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its affili...
GlobeNewswire · 06/01 12:30
Auris Medical's Affiliate to Launch Study in India Evaluating Efficacy of Bentrio Nasal Spray Against COVID-19
MT Newswires · 06/01 10:20
Auris Medical Announces Completion Of Bentrio Conformity Assessment Procedure For Marketing In EU
Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its
Benzinga · 05/25 13:07
Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated...
GlobeNewswire · 05/25 13:00
Auris Medical Says Conformity Assessment Procedure Now Complete for Potential CE Mark of Bentrio Nasal Spray
MT Newswires · 05/25 11:22
BRIEF-Auris Medical Reaches Midpoint For Enrollment In Part B Of AM-125 Phase 2 Travers Trial In Acute Peripheral Vertigo
reuters.com · 05/14 13:00
Webull provides a variety of real-time EARS stock news. You can receive the latest news about Auris Medical Holding Ltd through multiple platforms. This information may help you make smarter investment decisions.
About EARS
Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.